Latest papers

Regulation of Hepatic Lanosterol 14α-Demethylase Gene Expression by Dietary Cholesterol and Cholesterol-Lowering Agents

Determinants of variable response to statin treatment in patients with refractory familial hypercholesterolemia.

Colestipol-induced hepatotoxicity.

Common hepatic lipase gene promoter variant determines clinical response to intensive lipid-lowering treatment.

[Substantiation of increasing doses of statins in clinical practice]

The pharmacokinetics and pharmacodynamics of agents proven to raise high-density lipoprotein cholesterol.

Sorption of fluoroacetate (compound 1080) by Colestipol, activated charcoal and anion-exchange in resins in vitro and gastrointestinal decontamination in rats.

Efficacy of two lipid-lowering treatments on quantitative coronary angiographic endpoints.

Serial quantitative coronary angiography and coronary events

Correlations between measures of atherosclerosis change using carotid ultrasonography and coronary angiography.

Impact of pharmacy counseling on compliance and effectiveness of combination lipid-lowering therapy in patients undergoing coronary artery revascularization: a randomized, controlled trial.

Role of bile acids and bile acid binding agents in patients with collagenous colitis.

[Hyperhomocysteinemia].

Development of an unconventional in vitro drug release test method for a bile acid sequestrant, DMP 504, tablet.

Evidence for a new pathophysiological mechanism for coronary artery disease regression: hepatic lipase-mediated changes in LDL density.

The effect of the apolipoprotein E phenotype on cholesteryl ester transfer protein activity, plasma lipids and apolipoprotein A I levels in hypercholesterolaemic patients on colestipol and lovastatin treatment.

Role of colestipol in the treatment of hyperthyroidism.

Treating patients with documented atherosclerosis to National Cholesterol Education Program-recommended low-density-lipoprotein cholesterol goals with atorvastatin, fluvastatin, lovastatin and simvastatin.

Beneficial effect of a bile acid resin binder on enteral feeding induced diarrhea.

Use of niacin, statins, and resins in patients with combined hyperlipidemia.